-
Why metal prices are soaring to record highs
-
Stocks tepid in thin pre-Christmas trade
-
UN experts slam US blockade on Venezuela
-
Bethlehem celebrates first festive Christmas since Gaza war
-
Set-piece weakness costing Liverpool dear, says Slot
-
Two police killed in explosion in Moscow
-
EU 'strongly condemns' US sanctions against five Europeans
-
Arsenal's Kepa Arrizabalaga eager for more League Cup heroics against Che;sea
-
Thailand-Cambodia border talks proceed after venue row
-
Kosovo, Serbia 'need to normalise' relations: Kosovo PM to AFP
-
Newcastle boss Howe takes no comfort from recent Man Utd record
-
Frank warns squad to be 'grown-up' as Spurs players get Christmas Day off
-
Rome pushes Meta to allow other AIs on WhatsApp
-
Black box recovered from Libyan general's crashed plane
-
Festive lights, security tight for Christmas in Damascus
-
Zelensky reveals US-Ukraine plan to end Russian war, key questions remain
-
El Salvador defends mega-prison key to Trump deportations
-
Stranger Things set for final bow: five things to know
-
Grief, trauma weigh on survivors of catastrophic Hong Kong fire
-
Asian markets mixed after US growth data fuels Wall St record
-
Stokes says England player welfare his main priority
-
Australia's Lyon determined to bounce back after surgery
-
Stokes says England players' welfare his main priority
-
North Korean POWs in Ukraine seeking 'new life' in South
-
Japanese golf star 'Jumbo' Ozaki dies aged 78
-
Johnson, Castle shine as Spurs rout Thunder
-
Thai border clashes hit tourism at Cambodia's Angkor temples
-
From predator to plate: Japan bear crisis sparks culinary craze
-
Asian markets mostly up after US growth fuels Wall St record
-
'Happy milestone': Pakistan's historic brewery cheers export licence
-
Chevron: the only foreign oil company left in Venezuela
-
US denies visas to EU ex-commissioner, four others over tech rules
-
Dynamite Blockchain Delivers Record Q3 2025
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
SMX's Integrated Value Proposition: One System, Many Markets, Compounding Leverage
-
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
-
Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026
-
Pantheon Resources PLC Announces TR-1: Notification of Major Holdings
-
Bridgeline Expands Footprint with Closeout Retailer Choosing HawkSearch for Its On-Site Search Experience and Personalization
-
Koepka leaves LIV Golf: official
-
US slams China policies on chips but will delay tariffs to 2027
-
Arsenal reach League Cup semis with shoot-out win over Palace
-
Contenders Senegal, Nigeria start Cup of Nations campaigns with wins
-
Tunisia ease past Uganda to win Cup of Nations opener
-
S&P 500 surges to record after strong US economic report
-
UK police say no action against Bob Vylan duo over Israel army chant
-
Libya's top military chief killed in plane crash in Turkey
-
Venezuela passes law to jail backers of US oil blockade
-
French parliament passes emergency budget extension
Coalition of states vows to protect access to abortion pill under Trump review
A coalition of attorneys general across states including New York, Minnesota and Arizona vowed Monday to protect access to mifepristone, the medication used in the majority of abortions in the United States.
The move comes as the Trump administration has reportedly launched a review into the medication's safety, in what many abortion rights' organizations have dubbed a blatant attempt to undermine health care access.
"The decision to reexamine access to this medication was made in response to a scientifically baseless letter and ignores decades of research that prove mifepristone is safe and effective," read the joint statement that included New York's Attorney General Letitia James, who co-led the coalition of 20 officials in the effort.
"Medical decisions should be left between patients, their families, and their providers – and they should be guided by science, not political agendas," the statement continued.
"If access to mifepristone is challenged, we will take action to protect it," it added.
Officials who co-signed the initiative represented Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Washington state, and the District of Columbia.
Trump's health chief Robert F. Kennedy Jr and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying that the FDA was conducting its own review of the pill.
Proponents of reviewing mifepristone's safety have cited a study -- which was not peer-reviewed and published on a website, not in a scientific journal -- conducted by a conservative think-tank.
The Ethics & Public Policy Center (EPPC) says its priorities include "pushing back against the extreme progressive agenda while building a consensus for conservatives."
The medication has been used for 25 years in the United States. It is the most common method for abortion care and also routinely used for managing early miscarriage.
Mifepristone, which prevents pregnancy progression, and misoprostol, which empties the uterus, are approved to terminate a pregnancy up to 70 days of gestation in the United States.
A.Malone--AMWN